FDA Approves Experimental Hepatitis B Vaccine for Adults Despite Higher Incidence of Heart Attacks

Share it with your friends Like

Thanks! Share it with your friends!

Close

By AdminM

FDA Licenses New Hepatitis B Vaccine Despite Big Safety Concerns

by Rishma Parpia
The Vaccine Reaction

In February 2018, the Advisory Committee on Immunizations Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) approved the recommendation for a new hepatitis B vaccine, Heplisav-B (HepB-CpG) targeting for adults over the age of 18.1

Heplisav-B is manufactured by Dynavax Technologies Corp. and the new vaccine is given in a two-dose series versus the three dose recommendation for Merck’s Recombivax hepatitis B vaccine licensed in 1986 and Glaxo Smith Kline’s Engerix-B vaccine licensed in 1989.

The U.S. Food and Drug Administration (FDA) …read more

Source: Health Impact News

    

  • Rating:
  • Views:196 views
  • Categories: Health